Axis Bio

Bespoke preclinical research solutions supporting early drug discovery.

About Axis Bio

Founded in 2013 in Northern Ireland, Axis Bio is a preclinical contract research organization (CRO) specializing in early drug discovery. The company is recognized for its scientific expertise and collaborative approach, delivering tailored preclinical models that support informed decision-making in complex research programmes. In 2025, Axis Bio joined the QIMA group, strengthening QIMA Life Sciences’ scientific capabilities and expanding its international footprint across preclinical research services in oncology, immunology and metabolic disorders.

Services & Industries

Axis Bio supports clients across the pharmaceutical and biotechnology ecosystem with customized preclinical research services.

Services include:

  • In vitro and ex vivo efficacy and mechanistic studies

  • Preclinical pharmacology, PK/PD and biodistribution studies

  • Disease-relevant models in oncology, inflammation and respiratory research

  • Integrated bioanalysis, biomarker assessment and data interpretation

Industries served include:

  • Pharmaceutical companies

  • Biotechnology organizations

  • Academic and translational research institutions

What Sets Axis Bio Apart

Axis Bio is trusted for its ability to design fully bespoke scientific solutions aligned to each project’s research objectives. Its teams combine deep disease-area expertise with a partnership-driven mindset, acting as an extension of client research teams rather than a transactional service provider. Clients value the quality, reliability and interpretability of the data generated, as well as the agility and efficiency with which Axis Bio supports innovative and early-stage programmes.

Accreditations & Standards

Axis Bio operates in accordance with rigorous scientific, ethical and quality standards applicable to preclinical research. Its facilities, methodologies and data generation processes are designed to support robust, reliable and decision-ready preclinical outcomes in line with industry and regulatory expectations.

Part of QIMA

As part of the QIMA group, Axis Bio complements QIMA Life Sciences’ broader testing and research capabilities, extending support into early-stage drug discovery. This integration enables clients to access preclinical expertise alongside downstream testing, evaluation and compliance services within a single, globally recognized organization.

Get in Touch

To learn more about Axis Bio’s preclinical research capabilities and how they integrate with QIMA Life Sciences, contact our team.